EYPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
EyePoint Inc (EYPT) is not a strong buy for a beginner, long-term investor at this time. While the stock has bullish technical indicators, the company's financial performance is weak, with significant revenue declines and negative earnings. The options data suggests bearish sentiment in the short term, and there are no recent positive news catalysts or congress trading data to support a buy decision. Analysts remain optimistic with an Outperform rating and a raised price target, but the lack of immediate positive catalysts and the overbought RSI suggest waiting for a better entry point.
The stock shows bullish technical indicators with a positively expanding MACD histogram (0.588), overbought RSI (83.54), and bullish moving averages (SMA_5 > SMA_20 > SMA_200). However, the RSI indicates the stock is overbought, suggesting a potential pullback. Key resistance levels are at 17.406 and 18.73, with support at 13.12 and 11.796.
The company's Phase 3 LUGANO data for Duravyu is expected in mid-2026, which could be a long-term catalyst.
Additionally, there are no recent news catalysts or congress trading activity.
In Q3 2025, revenue dropped significantly by -90.82% YoY to $966,000. Net income improved to -$59.73M (up 103.44% YoY), and EPS increased to -0.85 (up 57.41% YoY). However, gross margin declined by -72.73% to 25.36%.
Mizuho raised the price target to $36 from $33 and maintains an Outperform rating. Analysts express confidence in EyePoint's thorough Phase 3 approach for Duravyu, despite competition from Ocular Therapeutix's Axpaxli.
